Eloxx Pharmaceuticals (NASDAQ:ELOX) Issues Quarterly Earnings Results

Eloxx Pharmaceuticals (NASDAQ:ELOX) issued its earnings results on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, Zacks reports.

Eloxx Pharmaceuticals Price Performance

ELOX stock traded up $2.18 during midday trading on Tuesday, reaching $19.18. The company had a trading volume of 51,268 shares, compared to its average volume of 57,978. The stock’s 50 day moving average price is $16.23. Eloxx Pharmaceuticals has a fifty-two week low of $8.20 and a fifty-two week high of $19.96. The stock has a market cap of $13.20 million, a price-to-earnings ratio of -1.25 and a beta of -1,864.08.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a research note on Saturday, August 1st. Guggenheim began coverage on Eloxx Pharmaceuticals in a report on Monday, July 20th. They issued a “buy” rating and a $43.00 price target for the company. Finally, Lifesci Capital began coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $41.50.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.